Skip to main content
Premium Trial:

Request an Annual Quote

RxGenomix, Coriell Life Sciences Form PGx Alliance

NEW YORK (GenomeWeb) — RxGenomix has partnered with Coriell Life Sciences (CLS) to offer a pharmacogenomics training, implementation, and management package to healthcare providers, the companies said today.

Under the terms of the alliance, the firms will combine Franklin, Tennessee-based RxGenomix's pharmacogenomics training and implementation program with CLS' bioinformatic services for risk analysis, reporting, and population-level healthcare analytics.

Additional terms were not disclosed.

"CLS brings the right mix of analytics capabilities along with rich scientific decision support, which accelerates RxGenomix's ability to deploy the most comprehensive and effective PGx offering in healthcare," RxGenomix COO Blake Keller said in a statement.

In late 2017, Philadelphia-based CLS signed an agreement with Ovation to integrate their respective data management and reporting technologies into a single platform.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.